Max Robotics — Global Service Robot Directory + US Certification

About

Marcus Scharpf is a leading figure in the advancement of prostate cancer diagnostics, with a primary focus on refining biopsy techniques through robotics and imaging integration. His major contributions center on the development and validation of robot-assisted transperineal fusion prostate biopsy, a method that combines magnetic resonance imaging (MRI) with real-time ultrasound to improve cancer detection accuracy. In his highly cited 2017 study (33 citations), Scharpf systematically compared targeted versus systematic biopsy approaches, providing critical evidence for optimizing diagnostic protocols in both primary and repeat biopsy settings. He further advanced the field by conducting a head-to-head comparison of biparametric and multiparametric MRI (19 citations, 2022), demonstrating that a streamlined MRI protocol could effectively guide targeted biopsies without compromising detection rates. Notably, Scharpf pioneered the first report on robot-assisted transperineal fusion versus off-target biopsy in repeat biopsy patients (2016, 16 citations), and his innovative work integrating computed tomographic ultrasound with artificial neural network analysis (2021) represents a novel, MRI-independent imaging strategy for detecting clinically significant prostate cancer. His cumulative research has directly shaped modern, less invasive diagnostic pathways, earning him recognition as a key innovator in urologic oncology.